New age-related regenerative medicine
"Stem cell research is one of the most exciting frontiers for bioscience."
Bob Duggan
OxStem is developing new approaches to age-related regenerative medicine, focusing on drugs that can treat cancer, neurodegenerative diseases, ocular diseases, diabetes, heart disease, macular degeneration, chronic inflammation, wound healing, and other major age-related conditions.
OxStem aims to work with partners at Oxford University to use stem cells and medicinal chemistry to identify new classes of drugs that can re-program or stimulate endogenous cells, awakening previously defunct or dormant cellular processes.
The company is an Oxford University spinout, founded in 2014 by Professor Steve Davies, Professor Dame Kay Davies, Professor Angela Russell, and several angel investors based in Oxford, UK. Bob Duggan has been an active investor through his associated interest in Human Longevity, Inc.
OxStem has formed a team with decades of experience in medicinal medicine. They are brilliantly aligning to design drugs that can “program resident stem and stem-like cells in situ to treat currently untreatable age-related conditions.”
OxStem Oncology is developing a universal differentiation therapy targeting hematological malignancies, focusing on acute myeloid leukemia (AML). The new medicine is expected to normalize hemopoiesis by differentiating leukemic myeloblasts resulting in complete durable remission for AML patients irrespective of their mutation status.
OxStem Ocular aims to identify new classes of drugs that can stimulate retinal precursor cells in patients with retinopathies such as dry age-related macular degeneration (dAMD) and retinitis pigmentosa. These new medicines are expected to induce retinal repair resulting in the restoration of vision.
OxStem Neuro has identified small molecules that can stimulate neural stem cells in situ resulting in neurogenesis and enhancement of cognitive function. As neurogenesis is compromised during aging and in neurodegenerative diseases such as Alzheimer’s, induction of neurogenesis represents a new therapeutic principle for such conditions.
OxStem Cardio aims to identify new classes of drugs that can stimulate cardiovascular cell regeneration from the activated epicardium and coronary lymphatic vessels. This is expected to restore lost tissue and improve cardiac function in cardiac disease conditions such as myocardial infarction.
OxStem Beta will develop therapeutics which stimulate regeneration of insulin-producing beta cells using small molecules diabetes.
OxStem Immuno’s underpinning technology aims to help stimulate tissue repair in chronic inflammation. The aim is to develop small molecules capable of switching macrophages from an infection-fighting anti-inflammatory phenotype, to treat chronic wounds such as diabetic foot ulcers.
OxStem appoints Dr. Ian Churcher as Chief Scientific Officer and announces further C-suite changes
06 Jan 2020
Go to linkOxStem appoints Chief Executive Officer
25 Mar 2019
Go to linkOxStem Beta and OxStem Immuno added to the portfolio of subsidiaries under the OxStem umbrella
04 Oct 2018
Go to linkOxford Stem Cell Institute Symposium 2018 – “Stem Cells: From Mechanism to Therapy”
24 Sep 2018
Go to linkOxStem appoints Chief Scientific Officer
10 Sep 2018
Go to linkThe cardiac lymphatic system stimulates resolution of inflammation following myocardial infarction – Prof. Paul Riley
26 Jul 2018
Go to linkThree Oxford researchers honoured by Royal Society
20 Jul 2018
Go to linkOxStem Presenting at Biotech Showcase, San Francisco
09 Jan 2018
Go to linkOxStem limited strengthens management team
09 Oct 2017
Go to linkTherapeutic developments: Masters of medicine
24 May 2017
Go to linkRecord £16.9m for Oxford spinout designing stem cell drugs to treat age-related disease
10 May 2016
Go to linkNow in development: off-the-shelf stem cells
27 Sep 2019
Go to link9 Regenerative medicine companies for living longer
20 Feb 2019
Go to linkOxford regenerative medicine spinout brings on GlaxoSmithKline drug hunter as CSO
10 Sep 2018
Go to linkThese are the best tech startups from Oxford University Innovation
27 Nov 2017
Go to linkOxford biotech deals highlight stature of UK university spinouts
10 May 2016
Go to link" OxStem...was founded with the goal of treating age-related diseases by regulating stem cells with small-molecule compounds."
Nature
17 May 2017
OxStem appoints Dr. Ian Churcher as Chief Scientific Officer and announces further C-suite changes
06 Jan 2020
OxStem appoints Chief Executive Officer
25 Mar 2019
OxStem Beta and OxStem Immuno added to the portfolio of subsidiaries under the OxStem umbrella
04 Oct 2018
Oxford Stem Cell Institute Symposium 2018 – “Stem Cells: From Mechanism to Therapy”
24 Sep 2018
OxStem appoints Chief Scientific Officer
10 Sep 2018
The cardiac lymphatic system stimulates resolution of inflammation following myocardial infarction – Prof. Paul Riley
26 Jul 2018
Three Oxford researchers honoured by Royal Society
20 Jul 2018
OxStem Presenting at Biotech Showcase, San Francisco
09 Jan 2018
OxStem limited strengthens management team
09 Oct 2017
Therapeutic developments: Masters of medicine
24 May 2017
Record £16.9m for Oxford spinout designing stem cell drugs to treat age-related disease
10 May 2016
Now in development: off-the-shelf stem cells
27 Sep 2019
9 Regenerative medicine companies for living longer
20 Feb 2019
Oxford regenerative medicine spinout brings on GlaxoSmithKline drug hunter as CSO
10 Sep 2018
These are the best tech startups from Oxford University Innovation
27 Nov 2017
Oxford biotech deals highlight stature of UK university spinouts
10 May 2016
Summit Therapeutics
Pulse Biosciences
Human Longevity Inc
OxStem
Pharmacyclics
Intuitive Surgical
Computer Motion
Metropolis Media
Communication Machinery Company
Government Technology Services
Paradise Bakery
Sunset Designs